ArticleBlood cancer journal2019

A phase 1 study of filanesib, carfilzomib, and dexamethasone in patients with relapsed and/or refractory multiple myeloma.

Hans C Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.